Cheol Whee Park

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5098698/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical predictors of recurrent cephalic arch stenosis and impact of the access flow reduction on the patency rate. Journal of Vascular Access, 2022, 23, 718-724.	0.9	1
2	Adiponectin receptor agonist ameliorates cardiac lipotoxicity via enhancing ceramide metabolism in type 2 diabetic mice. Cell Death and Disease, 2022, 13, 282.	6.3	19
3	Catalytic Antioxidants in the Kidney. Antioxidants, 2021, 10, 130.	5.1	33
4	Mortality prediction of serum neutrophil gelatinase-associated lipocalin in patients requiring continuous renal replacement therapy. Korean Journal of Internal Medicine, 2021, 36, 392-400.	1.7	4
5	MO631XANTHINE OXIDASE INHIBITOR AMELIORATES HIGH GLUCOSE-INDUCED OXIDATIVE STRESS BY ACTIVATING AMPK VIA THE ACTIVATION OF PURINE SALVAGE PATHWAY IN GLOMERULAR ENDOTHELIAL CELLS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
6	Cardiovascular Risk Comparison between Expanded Hemodialysis Using Theranova and Online Hemodiafiltration (CARTOON): A Multicenter Randomized Controlled Trial. Scientific Reports, 2021, 11, 10807.	3.3	13
7	MO629XANTHINE OXIDASE INHIBITOR ATTENUATES RENAL OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION THROUGH THE INHIBITION OF VEGF-NADPH OXIDASES IN DIABETIC NEPHROPATHY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
8	Fabry disease exacerbates renal interstitial fibrosis after unilateral ureteral obstruction via impaired autophagy and enhanced apoptosis. Kidney Research and Clinical Practice, 2021, 40, 208-219.	2.2	14
9	Renal Outcome of IgM Nephropathy: A Comparative Prospective Cohort Study. Journal of Clinical Medicine, 2021, 10, 4191.	2.4	2
10	Unilateral ptosis and painful ophthalmoplegia in a patient with kidney transplantation. American Journal of Transplantation, 2020, 20, 2951-2953.	4.7	0
11	P0135EFFECT OF LYSOPHOSPHATIDIC ACID REGULATION ON THE AGING KIDNEY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
12	The Impact of Obesity on the Severity of Clinicopathologic Parameters in Patients with IgA Nephropathy. Journal of Clinical Medicine, 2020, 9, 2824.	2.4	11
13	P0966PLACENTAL GROWTH FACTOR DEFICIENCY AGGRAVATES DIABETIC NEPHROPATHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
14	Acute kidney injury with extreme hyperuricemia after antithymocyte globulin treatment in a kidney transplant recipient with underlying aplastic anemia: a case report. BMC Nephrology, 2020, 21, 251.	1.8	4
15	Role of Renal Replacement Therapy During the Peri-Transplant Period of Heart Transplantation. Annals of Transplantation, 2020, 25, e925648.	0.9	1
16	Can management of the components of metabolic syndrome modify the course of chronic kidney disease?. Kidney Research and Clinical Practice, 2020, 39, 118-120.	2.2	5
17	Cilastatin Preconditioning Attenuates Renal Ischemia-Reperfusion Injury via Hypoxia Inducible Factor-1α Activation. International Journal of Molecular Sciences, 2020, 21, 3583.	4.1	8
18	Low parathyroid hormone level predicts infection-related mortality in incident dialysis patients: a prospective cohort study. Korean Journal of Internal Medicine, 2020, 35, 160-170.	1.7	16

#	Article	lF	CITATIONS
19	Recurrent Severe Hyponatremia in a Patient with Sjögren's Syndrome. Electrolyte and Blood Pressure, 2020, 18, 19.	1.8	4
20	Inhibition of xanthine oxidoreductase protects against contrast-induced renal tubular injury by activating adenosine monophosphate-activated protein kinase. Free Radical Biology and Medicine, 2019, 145, 209-220.	2.9	15
21	Autophagy attenuates tubulointerstital fibrosis through regulating transforming growth factor-β and NLRP3 inflammasome signaling pathway. Cell Death and Disease, 2019, 10, 78.	6.3	73
22	Intra-individual variability in high density lipoprotein cholesterol and risk of end-stage renal disease: A nationwide population-based study. Atherosclerosis, 2019, 286, 135-141.	0.8	10
23	The effect of vascular access type on intra-access flow volume during hemodialysis. Journal of Vascular Access, 2019, 20, 746-751.	0.9	0
24	Inhibition of lymphatic proliferation by the selective VEGFR-3 inhibitor SAR131675 ameliorates diabetic nephropathy in db/db mice. Cell Death and Disease, 2019, 10, 219.	6.3	44
25	Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease. International Journal of Molecular Sciences, 2019, 20, 1782.	4.1	63
26	Inhibition of p300/CBP-Associated Factor Attenuates Renal Tubulointerstitial Fibrosis through Modulation of NF-kB and Nrf2. International Journal of Molecular Sciences, 2019, 20, 1554.	4.1	42
27	Attenuated Lymphatic Proliferation Ameliorates Diabetic Nephropathy and High-Fat Diet-Induced Renal Lipotoxicity. Scientific Reports, 2019, 9, 1994.	3.3	22
28	Outcome of endovascular salvage of immature hemodialysis arteriovenous fistulas. Journal of Vascular Access, 2019, 20, 397-403.	0.9	8
29	Changing pattern and safety of pretransplant malignancy in kidney transplant recipients. Kidney Research and Clinical Practice, 2019, 38, 509-516.	2.2	4
30	Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease. Korean Journal of Internal Medicine, 2019, 34, 858-866.	1.7	20
31	Clinical outcomes and effects of treatment in older patients with idiopathic membranous nephropathy. Korean Journal of Internal Medicine, 2019, 34, 1091-1099.	1.7	12
32	Adiponectin receptor agonist AdipoRon decreased ceramide, and lipotoxicity, and ameliorated diabetic nephropathy. Metabolism: Clinical and Experimental, 2018, 85, 348-360.	3.4	106
33	Cinacalcet-mediated activation of the CaMKKβ-LKB1-AMPK pathway attenuates diabetic nephropathy in db/db mice by modulation of apoptosis and autophagy. Cell Death and Disease, 2018, 9, 270.	6.3	56
34	D‑Pinitol alleviates cyclosporine A‑induced renal tubulointerstitial fibrosis via activating Sirt1 and Nrf2 antioxidant pathways. International Journal of Molecular Medicine, 2018, 41, 1826-1834.	4.0	19
35	The protective effect of resveratrol on vascular aging by modulation of the renin–angiotensin system. Atherosclerosis, 2018, 270, 123-131.	0.8	104
36	The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2018, 29, 1108-1127.	6.1	140

#	Article	IF	CITATIONS
37	Exchange over the guidewire from non-tunneled to tunneled hemodialysis catheters can be performed without patency loss. Journal of Vascular Access, 2018, 19, 252-257.	0.9	3
38	Extracellular Superoxide Dismutase Attenuates Renal Oxidative Stress Through the Activation of Adenosine Monophosphate-Activated Protein Kinase in Diabetic Nephropathy. Antioxidants and Redox Signaling, 2018, 28, 1543-1561.	5.4	53
39	Calcimimetic restores diabetic peripheral neuropathy by ameliorating apoptosis and improving autophagy. Cell Death and Disease, 2018, 9, 1163.	6.3	42
40	Effects of Resveratrol on the Renin-Angiotensin System in the Aging Kidney. Nutrients, 2018, 10, 1741.	4.1	74
41	Clinical significance of the Kidney Donor Profile Index in deceased donors for prediction of post-transplant clinical outcomes: A multicenter cohort study. PLoS ONE, 2018, 13, e0205011.	2.5	6
42	Bilateral perirenal extraâ€adrenal myelolipoma in a haemodialysis patient. Nephrology, 2018, 23, 604-605.	1.6	0
43	Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients. Annals of Laboratory Medicine, 2018, 38, 450-457.	2.5	25
44	Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. Aging, 2018, 10, 83-99.	3.1	143
45	Clinical significance of the presence of anti-human leukocyte antigen-donor specific antibody in kidney transplant recipients with allograft dysfunction. Korean Journal of Internal Medicine, 2018, 33, 157-167.	1.7	7
46	Usefulness of assisted procedures for arteriovenous fistula maturation without compromising access patency. Hemodialysis International, 2017, 21, 335-342.	0.9	10
47	Clinical effects of pre-transplant serum 25-hydroxyvitamin D level on post-transplant immunologic and non-immunologic outcomes in kidney transplant recipients. Transplant Immunology, 2017, 40, 51-56.	1.2	11
48	Serum 1,25-dihydroxyvitamin D Better Reflects Renal Parameters Than 25-hydoxyvitamin D in Patients with Glomerular Diseases. International Journal of Medical Sciences, 2017, 14, 1080-1087.	2.5	5
49	Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E ₂ Receptor EP4 Pathway. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-17.	4.0	11
50	Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. PLoS ONE, 2017, 12, e0181757.	2.5	17
51	Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease. Tohoku Journal of Experimental Medicine, 2017, 242, 281-290.	1.2	10
52	New therapeutic agents in diabetic nephropathy. Korean Journal of Internal Medicine, 2017, 32, 11-25.	1.7	48
53	Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection. Annals of Transplantation, 2017, 22, 468-474.	0.9	5
54	Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea. Kidney Research and Clinical Practice, 2017, 36, 68-78.	2.2	32

#	Article	IF	CITATIONS
55	Paricalcitol attenuates lipopolysaccharide-induced inflammation and apoptosis in proximal tubular cells through the prostaglandin E2 receptor EP4. Kidney Research and Clinical Practice, 2017, 36, 145-158.	2.2	11
56	Response to comment on "New therapeutic agents in diabetic nephropathy― Korean Journal of Internal Medicine, 2017, 32, 570-570.	1.7	2
57	Age-Associated Changes in the Vascular Renin-Angiotensin System in Mice. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-14.	4.0	105
58	Clinical Significance of Pre- and Post-Transplant BAFF Levels in Kidney Transplant Recipients. PLoS ONE, 2016, 11, e0162964.	2.5	12
59	Resveratrol increases AdipoR1 and AdipoR2 expression in type 2 diabetic nephropathy. Journal of Translational Medicine, 2016, 14, 176.	4.4	64
60	Clinical significance of red blood cell distribution width in the prediction of mortality in patients on peritoneal dialysis. Kidney Research and Clinical Practice, 2016, 35, 114-118.	2.2	13
61	Acute kidney injury induced by thrombotic microangiopathy in a patient with hemophagocytic lymphohistiocytosis. BMC Nephrology, 2016, 17, 4.	1.8	18
62	Systematic biomarker discovery and coordinative validation for different primary nephrotic syndromes using gas chromatography–mass spectrometry. Journal of Chromatography A, 2016, 1453, 105-115.	3.7	27
63	PPARα agonist, fenofibrate, ameliorates age-related renal injury. Experimental Gerontology, 2016, 81, 42-50.	2.8	32
64	Adenosine monophosphate–activated protein kinase in diabetic nephropathy. Kidney Research and Clinical Practice, 2016, 35, 69-77.	2.2	64
65	The protective effect of neutralizing high-mobility group box1 against chronic cyclosporine nephrotoxicity in mice. Transplant Immunology, 2016, 34, 42-49.	1.2	10
66	Serum Anion Gap Predicts All-Cause Mortality in Patients with Advanced Chronic Kidney Disease: A Retrospective Analysis of a Randomized Controlled Study. PLoS ONE, 2016, 11, e0156381.	2.5	11
67	Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors. Korean Journal of Internal Medicine, 2016, 31, 552-559.	1.7	7
68	T-type calcium channel blocker attenuates unilateral ureteral obstruction-induced renal interstitial fibrosis by activating the Nrf2 antioxidant pathway. American Journal of Translational Research (discontinued), 2016, 8, 4574-4585.	0.0	7
69	Anthocyanin-rich Seoritae extract ameliorates renal lipotoxicity via activation of AMP-activated protein kinase in diabetic mice. Journal of Translational Medicine, 2015, 13, 203.	4.4	48
70	Fimasartan, a Novel Angiotensin-Receptor Blocker, Protects against Renal Inflammation and Fibrosis in Mice with Unilateral Ureteral Obstruction: the Possible Role of Nrf2. International Journal of Medical Sciences, 2015, 12, 891-904.	2.5	40
71	FP202PARICALCITOL PRETREATMENT ATTENUATES APOPTOSIS AND INFLAMMATION IN RENAL ISCHEMIA-REPERFUSION INJURY VIA PROSTAGLANDIN E2 RECEPTOR EP4. Nephrology Dialysis Transplantation, 2015, 30, iii134-iii135.	0.7	0
72	FP299THE PPAR-α AGONIST, FENOFIBRATE, AMELIORATES AGING-RELATED PROGRESSIVE RENAL INJURY. Nephrology Dialysis Transplantation, 2015, 30, iii167-iii167.	0.7	0

#	Article	IF	CITATIONS
73	Tenofovirâ€associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection. Hepatology, 2015, 62, 1318-1320.	7.3	27
74	The impact of kidney transplantation on 24–hour ambulatory blood pressure in end–stage renal disease patients. Journal of the American Society of Hypertension, 2015, 9, 427-434.	2.3	13
75	Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease. Clinical and Experimental Nephrology, 2015, 19, 208-215.	1.6	15
76	Impact of ABO Incompatibility on the Development of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients Presensitized to HLA. PLoS ONE, 2015, 10, e0123638.	2.5	16
77	Henoch-Schönlein purpura secondary to infective endocarditis in a patient with pulmonary valve stenosis and a ventricular septal defect. Korean Journal of Internal Medicine, 2015, 30, 406.	1.7	6
78	Immunologic and non-immunologic complications of a third kidney transplantation. Korean Journal of Internal Medicine, 2015, 30, 657-664.	1.7	6
79	Risk factors in the progression of BK virus-associated nephropathy in renal transplant recipients. Korean Journal of Internal Medicine, 2015, 30, 865-872.	1.7	14
80	Vascular Endothelial Growth Factor-Receptor 1 Inhibition Aggravates Diabetic Nephropathy through eNOS Signaling Pathway in db/db Mice. PLoS ONE, 2014, 9, e94540.	2.5	28
81	Fenofibrate Improves Renal Lipotoxicity through Activation of AMPK-PGC-1α in db/db Mice. PLoS ONE, 2014, 9, e96147.	2.5	87
82	Benefits of a Continuous Ambulatory Peritoneal Dialysis (CAPD) Technique with One Icodextrin-Containing and Two Biocompatible Glucose-Containing Dialysates for Preservation of Residual Renal Function and Biocompatibility in Incident CAPD Patients. Journal of Korean Medical Science, 2014, 29, 1217.	2.5	9
83	Use of Bortezomib as Anti-Humoral Therapy in Kidney Transplantation. Journal of Korean Medical Science, 2014, 29, 648.	2.5	18
84	The Effect of Combination Therapy with Rituximab and Intravenous Immunoglobulin on the Progression of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. Journal of Immunology Research, 2014, 2014, 1-7.	2.2	10
85	Clinical outcome of kidney transplantation from deceased donors with acute kidney injury by Acute Kidney Injury Network criteria. Journal of Critical Care, 2014, 29, 432-437.	2.2	37
86	Aggravation of diabetic nephropathy in BCL-2 interacting cell death suppressor (BIS)-haploinsufficient mice together with impaired induction of superoxide dismutase (SOD) activity. Diabetologia, 2014, 57, 214-223.	6.3	12
87	Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy. Transplant Immunology, 2014, 31, 140-144.	1.2	13
88	Decrease of immature B cell and interleukin-10 during early-post-transplant period in renal transplant recipients under tacrolimus based immunosuppression. Transplant Immunology, 2014, 30, 159-167.	1.2	25
89	Therapeutic Effects of Fenofibrate on Diabetic Peripheral Neuropathy by Improving Endothelial and Neural Survival in db/db Mice. PLoS ONE, 2014, 9, e83204.	2.5	33
90	Niacin in patients with chronic kidney disease: Is it effective and safe?. Kidney Research and Clinical Practice, 2013, 32, 1-2.	2.2	6

#	Article	IF	CITATIONS
91	Comparison of in vivo biocompatibilities between parylene-C and polydimethylsiloxane for implantable microelectronic devices. Bulletin of Materials Science, 2013, 36, 1127-1132.	1.7	9
92	De novo glomerulitis associated with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: A single-center experience. Kidney Research and Clinical Practice, 2013, 32, 121-126.	2.2	11
93	Vascular Endothelial Growth Factor Inhibition by dRK6 Causes Endothelial Apoptosis, Fibrosis, and Inflammation in the Heart via the Akt/eNOS Axis in <i>db/db</i> Mice. Diabetes, 2009, 58, 2666-2676.	0.6	44
94	Long-Term Treatment of Glucagon-Like Peptide-1 Analog Exendin-4 Ameliorates Diabetic Nephropathy through Improving Metabolic Anomalies in db/db Mice. Journal of the American Society of Nephrology: JASN, 2007, 18, 1227-1238.	6.1	195
95	Accelerated Diabetic Nephropathy in Mice Lacking the Peroxisome Proliferator–Activated Receptor α. Diabetes, 2006, 55, 885-893.	0.6	133
96	Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. American Journal of Kidney Diseases, 2002, 40, 1230-1239.	1.9	65